Display options
Share it on

Cytotechnology. 1997 Jan;23(1):151-9. doi: 10.1023/A:1007980032042.

Building high affinity human antibodies by altering the glycosylation on the light chain variable region in N-acetylglucosamine-supplemented hybridoma cultures.

Cytotechnology

H Tachibana, J Y Kim, S Shirahata

Affiliations

  1. Graduate School of Genetic Resources Technology, Kyushu University, Hakozaki, Higashi-ku, Fukuoka, 812, Japan.

PMID: 22358531 PMCID: PMC3449873 DOI: 10.1023/A:1007980032042

Abstract

We attempted to improve antibody affinity by varying glycosylation on the light chain variable region. The human hybridoma line HB4C5 produces an antibody reactive to lung adenocarcinoma, which possess a N-glycosylated carbohydrate chain on the light chain hypervariable region. It has been shown that altering this carbohydrate structure can be accomplished by varying the level of N-acetylglucosamine in glucose free medium, a change in the carbohydrate chain could be induced which resulted in modifying antigen binding. By culturing the cells in media containing more than 20 mM N-acetylglucosamine, cells produced antibody with 10 fold improved affinity as compared with antibody produced in 20 mM glucose-containing medium. A newly induced light chain glycoform produced in the N-acetylglucosamine-containing medium was shown to be responsible for this antigen binding enhancement. Addition of glucose in the N-acetylglucosamine-containing media led to decreased antibody affinity and slightly inhibited production of a new light chain in a dose-dependent manner. Combination of 20 mM N-acetylglucosamine and 0.5 mM glucose gave a higher antibody production without the decrease of the antigen binding. These results indicate that optimization of N-glycosylation on the light chain, which leads to higher antigen binding, can be accomplished by adjusting a ratio of glucose and N-acetylglucosamine in the culture medium.

References

  1. Biochem Biophys Res Commun. 1992 Dec 15;189(2):625-32 - PubMed
  2. In Vitro Cell Dev Biol Anim. 1996 Mar;32(3):178-83 - PubMed
  3. Biochim Biophys Acta. 1993 Oct 20;1182(3):257-63 - PubMed
  4. In Vitro Cell Dev Biol. 1985 Oct;21(10):593-6 - PubMed
  5. Arch Biochem Biophys. 1980 Dec;205(2):330-9 - PubMed
  6. Arch Biochem Biophys. 1979 Feb;192(2):599-609 - PubMed
  7. Biotechnology (N Y). 1991 Dec;9(12):1347-55 - PubMed
  8. Hum Antibodies Hybridomas. 1993 Jan;4(1):9-14 - PubMed
  9. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 - PubMed
  10. J Surg Oncol. 1988 Oct;39(2):108-13 - PubMed
  11. Biochem J. 1990 Dec 1;272(2):333-7 - PubMed
  12. J Biol Chem. 1981 Jun 25;256(12):6255-61 - PubMed
  13. J Mol Biol. 1987 Aug 20;196(4):901-17 - PubMed
  14. Cytotechnology. 1994;16(3):151-7 - PubMed
  15. Hum Antibodies Hybridomas. 1991 Apr;2(2):51-6 - PubMed
  16. J Biol Chem. 1988 Nov 25;263(33):17508-15 - PubMed
  17. Biochim Biophys Acta. 1964 Apr 4;86:149-55 - PubMed
  18. Proc Natl Acad Sci U S A. 1982 Feb;79(4):1158-62 - PubMed
  19. Hum Antibodies Hybridomas. 1991 Jul;2(3):142-7 - PubMed
  20. Proc Natl Acad Sci U S A. 1970 Jul;66(3):975-82 - PubMed
  21. Biochem Biophys Res Commun. 1977 Apr 25;75(4):838-44 - PubMed

Publication Types